ES2072504T3 - Derivados de bencimidazol, su preparacion y uso. - Google Patents

Derivados de bencimidazol, su preparacion y uso.

Info

Publication number
ES2072504T3
ES2072504T3 ES91116148T ES91116148T ES2072504T3 ES 2072504 T3 ES2072504 T3 ES 2072504T3 ES 91116148 T ES91116148 T ES 91116148T ES 91116148 T ES91116148 T ES 91116148T ES 2072504 T3 ES2072504 T3 ES 2072504T3
Authority
ES
Spain
Prior art keywords
hydrogen
halogen
alkyl
independently
bencimidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91116148T
Other languages
English (en)
Inventor
Soren-Peter Olesen
Frank Watjen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Application granted granted Critical
Publication of ES2072504T3 publication Critical patent/ES2072504T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Graft Or Block Polymers (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

UN COMPUESTO QUE TIENE LA FORMULA EN DONDE R ELEVADO 1 ES HIDROGENO, NH SUB 2 O ALQUILO C SUB 1 6 QUE PUEDE SER RAMIFICADO; X ES O, S, NCN; Y ES O, S; R ELEVADO 4, R ELEVADO 5, R ELEVADO 6 Y R ELEVADO 7 SON CADA UNO INDEPENDIENTEMENTE, HIDROGENO, HALOGENO, CF SUB 3, NO SUB 2, NH SUB 2, OH, ALCOXI C SUB 1 6, C(=O)-FENILO O SO SUB 2 NR ELEVADO * R ELEVADO * EN DONDE R ELEVADO * Y R ELEVADO * SON INDEPENDIENTEMENTE HIDROGENO O ALQUILO C SUB 1 6; R ELEVADO 11 ES HIDROGENO, HALOGENO, NO SUB 2 O SO SUB 2 NR''R'''' EN DONDE R'' Y R'''' SON INDEPENDIENTEMENTE HIDROGENO O ALQUILO C SUB 1 6; R ELEVADO 13 ES HIDROGENO, HALOGENO, FENILO, CF SUB 3, NO SUB 2; R ELEVADO 12 ES HIDROGENO O JUNTO CON R ELEVADO 13 FORMA UN ANILLO CARBOCICLICO C SUB 4 7 QUE PUEDE SER AROMATICO O SATURADO EN PARTE; ADEMAS, UN METODO PARA TRATAR UNA ENFERMEDAD EN UN MAMIFERO, INCLUIDA UNA PERSONA HUMANA, QUE RESPONDE A LA ABERTURA DE CANALES DE POTASIO, QUE CONSISTE EN ADMINISTRAR A UN MAMIFERO QUE LO NECESITA, UNA CANTIDAD EFICAZ DEUN COMPUESTO COMO EL PRIMERO ARRIBA MENCIONADO.
ES91116148T 1990-09-24 1991-09-23 Derivados de bencimidazol, su preparacion y uso. Expired - Lifetime ES2072504T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58690090A 1990-09-24 1990-09-24

Publications (1)

Publication Number Publication Date
ES2072504T3 true ES2072504T3 (es) 1995-07-16

Family

ID=24347548

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91116148T Expired - Lifetime ES2072504T3 (es) 1990-09-24 1991-09-23 Derivados de bencimidazol, su preparacion y uso.

Country Status (15)

Country Link
EP (1) EP0477819B1 (es)
JP (1) JP3203017B2 (es)
KR (1) KR100195770B1 (es)
AT (1) ATE119887T1 (es)
AU (1) AU635440B2 (es)
CA (1) CA2052041C (es)
DE (1) DE69108156T2 (es)
DK (1) DK0477819T3 (es)
ES (1) ES2072504T3 (es)
FI (1) FI103408B1 (es)
IE (1) IE67133B1 (es)
NO (1) NO180795C (es)
NZ (1) NZ239540A (es)
PT (1) PT99032B (es)
ZA (1) ZA916805B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0520200T3 (da) * 1991-06-24 1998-09-23 Neurosearch As Imadazol-forbindelser, deres fremstilling og anvendelse
US5158969A (en) * 1991-08-21 1992-10-27 Neurosearch A/S Indole derivatives as potassium channel blockers
US5232899A (en) * 1992-06-08 1993-08-03 Imperial Chemical Industries Plc Benzoxazolinones and their use as herbicides
WO1994011355A1 (en) * 1992-11-19 1994-05-26 Dainippon Pharmaceutical Co., Ltd. 3,4-dihydro-1-(2-hydroxyphenyl)-2(1h)-quinoxalinone derivative and related compound
DK154092D0 (da) * 1992-12-23 1992-12-23 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
DK28893D0 (da) * 1993-03-15 1993-03-15 Neurosearch As Benzimidazole derivater, deres fremstilling og anvendelse
DK41193D0 (da) * 1993-04-07 1993-04-07 Neurosearch As Ionkanalaabnere
US5637470A (en) * 1994-05-13 1997-06-10 Merck & Co., Inc. Screening array using cells expressing recombinant α and β subunits of the mammalian large-conductance (maxi-K) potassium channel
FR2722190B1 (fr) * 1994-07-05 1996-10-04 Sanofi Sa Derives de 1-benzyl-1,3-dihydro-2h-benzimidazol-2-one, leur preparation, les compositions pharmaceutique en contenant
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
TW504504B (en) * 1996-11-26 2002-10-01 Bristol Myers Squibb Co 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators
US5893085A (en) * 1997-06-10 1999-04-06 Phillips; Ronald W. Dynamic fuzzy logic process for identifying objects in three-dimensional data
AU742452B2 (en) * 1997-08-28 2002-01-03 Bristol-Myers Squibb Company 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators
US6184231B1 (en) 1998-12-04 2001-02-06 Bristol-Myers Squibb 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
EP1144387A1 (en) * 1998-12-04 2001-10-17 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
AU2003240427A1 (en) 2002-06-26 2004-01-19 Poseidon Pharmaceuticals A/S Novel benzimidazol-2-one derivatives and their use
WO2004064835A1 (en) * 2003-01-17 2004-08-05 Neurosearch A/S Use of ion channel modulating agents for treating pain
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
PE20060572A1 (es) * 2004-07-27 2006-06-27 Novartis Ag Compuestos de benzoimidazolona como inhibidores de hsp90
MX2009010296A (es) * 2007-04-18 2009-12-14 Kissei Pharmaceutical Derivado de anillo fusionado nitrogenado, composicion farmaceutica que lo contiene, y uso del mismo para propositos medicos.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH460028A (de) * 1965-01-22 1968-07-31 Wander Ag Dr A Verfahren zur Herstellung von Benzimidazolonderivaten
FR1561830A (es) * 1968-05-08 1969-03-28
GB1408408A (en) * 1971-11-24 1975-10-01 Beecham Group Ltd Benzimidazole derivatives
GB1476949A (en) * 1974-11-20 1977-06-16 Wyeth John & Brother Ltd Imidazo-1,2-a-benzimidazole and pyrimido-1,2-a-benzimidazole derivatives their preparation and their pharmaceutical compositions
CH622009A5 (es) * 1976-06-11 1981-03-13 Ciba Geigy Ag
DE3042481A1 (de) * 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln (omega)-(2-oxo-benzazolinyl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
EP0232937B1 (en) * 1986-02-03 1992-08-19 Janssen Pharmaceutica N.V. Anti-histaminic compositions containing n-heterocyclyl-4-piperidinamines

Also Published As

Publication number Publication date
DE69108156D1 (de) 1995-04-20
JPH04305568A (ja) 1992-10-28
ATE119887T1 (de) 1995-04-15
FI103408B (fi) 1999-06-30
DK0477819T3 (da) 1995-07-17
NO913728D0 (no) 1991-09-23
NO913728L (no) 1992-03-25
EP0477819B1 (en) 1995-03-15
PT99032A (pt) 1993-11-30
FI914275A0 (fi) 1991-09-11
IE913197A1 (en) 1992-02-25
PT99032B (pt) 1999-02-26
FI914275A (fi) 1992-03-25
DE69108156T2 (de) 1995-07-06
JP3203017B2 (ja) 2001-08-27
KR100195770B1 (ko) 1999-06-15
NO180795C (no) 1997-06-25
NZ239540A (en) 1993-11-25
IE67133B1 (en) 1996-03-06
EP0477819A2 (en) 1992-04-01
ZA916805B (en) 1992-05-27
EP0477819A3 (en) 1992-05-20
CA2052041A1 (en) 1992-03-25
AU635440B2 (en) 1993-03-18
FI103408B1 (fi) 1999-06-30
AU8276791A (en) 1992-03-26
KR920006327A (ko) 1992-04-27
CA2052041C (en) 2002-08-20
NO180795B (no) 1997-03-17

Similar Documents

Publication Publication Date Title
ES2072504T3 (es) Derivados de bencimidazol, su preparacion y uso.
DE69010139T2 (de) Haarkräftigungsmittel.
TR199901674T2 (es)
ATE88699T1 (de) Oxidierte diphenylheteroalkane, ihre herstellung und verwendung.
ES507994A0 (es) Un procedimiento para la preparacion de un compuesto de quinazolina.
DE69017511T2 (de) Butenoinsäure-Derivate.
FR2361345A1 (fr) Homologues de somatostatine, sa preparation et son utilisation therapeutique
IT8748212A0 (it) Composti monoazoici, loro preparazione e loro impiego come coloranti
ES2123741T3 (es) Derivados de bencimidazol, su preparacion y uso.
FR2601021B2 (fr) Fraction immunogene active a l'egard des bilharzioses, sa preparation, compositions immunisantes la contenant
PT78155B (de) N-(3-trifluormethylphenyl)-n'-propargylpiperazin seine herstellung und verwendung
EA199901065A1 (ru) Фунгицидные смеси
IT8748355A0 (it) Composti monoazoici,loro preparazione e loro impiego come coloranti
ATE198750T1 (de) Isatinoxim-derivate, ihre herstellung und verwendung
SE9201188L (sv) Ny användning
SE7910612L (sv) Metod att kontrollera hypertension och intestinala sjukdomar samt kompositioner
ATE114307T1 (de) Phenylglycidamide, verwendbar in der herstellung von alpha-hydroxy-beta-sulfido-arylpropionsäure- derivaten.
JPS53119825A (en) 1,3-dithioallophanate derivatives, their preparation, insecticides, acaricides, and bactericides for agricultural and horticultural uses
IT8748146A0 (it) Composti monoazoici, loro preparazione e loro impiego come coloranti

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 477819

Country of ref document: ES